Home/Pipeline/Prescription Dermatology & Eye Care Products

Prescription Dermatology & Eye Care Products

Specific dermatological and ophthalmological conditions

Approved/CommercialRelaunched (2024)

Key Facts

Indication
Specific dermatological and ophthalmological conditions
Phase
Approved/Commercial
Status
Relaunched (2024)
Company

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals leverages its proprietary Microcyn® Technology, the world's first patented and shelf-stable hypochlorous acid formulation, to address a broad range of infection control and skin health needs. With a global presence in over 50 countries, a portfolio backed by numerous patents and regulatory approvals, and a product line spanning wound care, dermatology, and consumer health, the company is positioned as a leader in HOCl-based solutions. Its strategic direction includes expanding direct offerings in dermatology and eye care, while pursuing wholesale, partnership, and distributor opportunities to grow its market reach.

View full company profile